Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

13.81 -6.30 (-31.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bicycle Therapeutics Plc ADR

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification. 
Via Benzinga
Navigating 11 Analyst Ratings For Bicycle Therapeutics
Via Benzinga
BCYC: A Promising Play In The Biotech Sector
The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a... 
Via Talk Markets
Topics ETFs
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics
Via Benzinga
The Latest Analyst Ratings For Bicycle Therapeutics
Via Benzinga
Expert Ratings For Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033... 
Via Benzinga
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Gold Falls Sharply; US Composite PMI Surges In May
Via Benzinga
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Via Benzinga
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Bicycle Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Bicycle Therapeutics
Via Benzinga
Where Bicycle Therapeutics Stands With Analysts
Via Benzinga
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Shares of Bicycle Therapeutics Were Rising on Monday
The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy. 
Via The Motley Fool
Exposures Product Safety
Expert Ratings for Bicycle Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Why Bicycle Therapeutics Stock Raced Ahead Today
The company's latest attempt at capital raising seems to be having enviable success. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) gained 18% to... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.